{"id":"csf1r","name":"CSF1R","symbol":"CSF1R","route":"/targets/csf1r/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2433","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182578","uniprot":"https://www.uniprot.org/uniprotkb/P07333/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P07333","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1844","open-targets":"https://platform.opentargets.org/target/ENSG00000182578","civic":"https://civicdb.org/genes/1436/summary","oncokb":"https://www.oncokb.org/gene/CSF1R","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF1R","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CSF1R","depmap":"https://depmap.org/portal/gene/CSF1R?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000182578-CSF1R","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1436","omim":"https://www.omim.org/entry/164770"}],"products":[{"id":"chiauranib","name":"Chiauranib","status":"phase-3","modality":"small molecule","route":"/drugs/chiauranib/"},{"id":"emactuzumab","name":"Emactuzumab","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/emactuzumab/"},{"id":"pexidartinib","name":"Pexidartinib","status":"approved","modality":"Small-molecule CSF1R/KIT/FLT3 inhibitor","route":"/drugs/pexidartinib/"},{"id":"surufatinib","name":"Surufatinib","status":"approved","modality":"Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor","route":"/drugs/surufatinib/"}],"trials":[{"id":"nct04488822","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","nct":"NCT04488822","phase":"3","status":"active"},{"id":"sanet","name":"SANET-ep and SANET-p","nct":"NCT02588170","phase":"3","status":"positive"},{"id":"enliven","name":"ENLIVEN","nct":"NCT02371369","phase":"3","status":"positive"},{"id":"nct03768063","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","nct":"NCT03768063","phase":"3","status":"active"},{"id":"nct04921527","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","nct":"NCT04921527","phase":"3","status":"recruiting"},{"id":"nct05417789","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","nct":"NCT05417789","phase":"3","status":"active"},{"id":"nct06361888","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","nct":"NCT06361888","phase":"2/3","status":"recruiting"},{"id":"nct06654947","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","nct":"NCT06654947","phase":"2","status":"planned"},{"id":"nct06708858","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","nct":"NCT06708858","phase":"2","status":"recruiting"},{"id":"nct05988372","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","nct":"NCT05988372","phase":"2","status":"planned"},{"id":"nct06531291","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","nct":"NCT06531291","phase":"2","status":"planned"},{"id":"nct07469956","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","nct":"NCT07469956","phase":"2","status":"planned"}],"pathways":["immune-desert-exclusion","complement-in-cancer","intravasation-ctc-survival","myeloid-suppression-axis","nutrient-competition-tme","angiogenic-switch","pre-metastatic-niche"],"companies":["abbisko","chipscreen","daiichi-sankyo","hutchmed","qurient","roche-genentech"],"keyPapers":["paper-tap-lancet","paper-quail-joyce-microenvironment-metastasis-natmed-2013"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}